Grand Pharmaceutical Group Past Earnings Performance
Past criteria checks 2/6
Grand Pharmaceutical Group has been growing earnings at an average annual rate of 17.5%, while the Pharmaceuticals industry saw earnings growing at 9.7% annually. Revenues have been growing at an average rate of 13.1% per year. Grand Pharmaceutical Group's return on equity is 12.4%, and it has net margins of 17.9%.
Key information
17.5%
Earnings growth rate
14.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 13.1% |
| Return on equity | 12.4% |
| Net Margin | 17.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Grand Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 10,530 | 1,880 | 3,802 | 0 |
| 30 Sep 23 | 10,434 | 2,139 | 3,694 | 0 |
| 30 Jun 23 | 10,339 | 2,398 | 3,586 | 0 |
| 31 Mar 23 | 9,951 | 2,239 | 3,381 | 0 |
| 31 Dec 22 | 9,562 | 2,079 | 3,177 | 0 |
| 30 Sep 22 | 9,403 | 1,995 | 3,282 | 0 |
| 30 Jun 22 | 9,244 | 1,910 | 3,387 | 0 |
| 31 Mar 22 | 8,921 | 2,156 | 3,347 | 0 |
| 31 Dec 21 | 8,598 | 2,403 | 3,307 | 0 |
| 30 Sep 21 | 8,131 | 2,340 | 3,217 | 0 |
| 30 Jun 21 | 7,664 | 2,277 | 3,126 | 0 |
| 31 Mar 21 | 7,008 | 2,035 | 2,836 | 0 |
| 31 Dec 20 | 6,353 | 1,793 | 2,545 | 0 |
| 30 Sep 20 | 6,306 | 1,558 | 2,534 | 0 |
| 30 Jun 20 | 6,259 | 1,323 | 2,523 | 0 |
| 31 Mar 20 | 6,425 | 1,237 | 2,686 | 0 |
| 31 Dec 19 | 6,591 | 1,151 | 2,849 | 0 |
| 30 Sep 19 | 6,450 | 1,048 | 2,688 | 0 |
| 30 Jun 19 | 6,309 | 944 | 2,526 | 0 |
| 31 Mar 19 | 6,134 | 828 | 2,419 | 0 |
| 31 Dec 18 | 5,958 | 713 | 2,312 | 0 |
| 30 Sep 18 | 5,845 | 642 | 2,364 | 0 |
| 30 Jun 18 | 5,732 | 570 | 2,415 | 0 |
| 31 Mar 18 | 5,251 | 516 | 2,141 | 0 |
| 31 Dec 17 | 4,771 | 461 | 1,867 | 0 |
| 30 Sep 17 | 4,480 | 413 | 1,728 | 0 |
| 30 Jun 17 | 4,190 | 364 | 1,590 | 0 |
| 31 Mar 17 | 3,943 | 317 | 1,457 | 0 |
| 31 Dec 16 | 3,696 | 269 | 1,324 | 0 |
| 30 Sep 16 | 3,573 | 241 | 1,245 | 0 |
| 30 Jun 16 | 3,450 | 213 | 1,167 | 0 |
| 31 Mar 16 | 3,348 | 197 | 1,119 | 0 |
| 31 Dec 15 | 3,246 | 181 | 1,071 | 0 |
| 30 Sep 15 | 3,158 | 187 | 1,021 | 0 |
| 30 Jun 15 | 3,071 | 194 | 971 | 0 |
| 31 Mar 15 | 3,097 | 185 | 976 | 0 |
| 31 Dec 14 | 3,122 | 175 | 981 | 0 |
| 30 Sep 14 | 3,040 | 150 | 932 | 0 |
| 30 Jun 14 | 2,958 | 126 | 884 | 0 |
| 31 Mar 14 | 2,808 | 113 | 828 | 0 |
| 31 Dec 13 | 2,658 | 100 | 772 | 0 |
| 30 Sep 13 | 2,493 | 91 | 709 | 0 |
| 30 Jun 13 | 2,328 | 82 | 646 | 0 |
Quality Earnings: MX6A has high quality earnings.
Growing Profit Margin: MX6A's current net profit margins (17.9%) are lower than last year (21.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MX6A's earnings have grown by 17.5% per year over the past 5 years.
Accelerating Growth: MX6A's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MX6A had negative earnings growth (-9.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (3%).
Return on Equity
High ROE: MX6A's Return on Equity (12.4%) is considered low.